Pancreatic Cancer Research

ResearcherShanghai UniversityActive in the last 2 years

Jiancheng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1651-8977; OpenAlex author ID A5100599544. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers

Papers 7

  1. MicroRNA-130b Suppresses Malignant Behaviours and Inhibits the Activation of the PI3K/Akt Signaling Pathway by Targeting MET in Pancreatic Cancer. Co-author DOI 10.1007/s10528-024-10696-7↗
  2. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Co-author DOI 10.1038/s41418-024-01423-1↗
  3. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-1516835/v1↗
  4. MicroRNA-221-3p is related to survival and promotes tumour progression in pancreatic cancer: a comprehensive study on functions and clinicopathological value. Co-author DOI 10.1186/s12935-020-01529-9↗
  5. Long non-coding RNA LINC01133 silencing exerts antioncogenic effect in pancreatic cancer through the methylation of DKK1 promoter and the activation of Wnt sig… Last author DOI 10.1080/15384047.2018.1529110↗
  6. EZH2-Mediated microRNA-139-5p Regulates Epithelial-Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer. Last author DOI 10.14348/molcells.2018.0109↗
  7. The ABCC4 gene is a promising target for pancreatic cancer therapy. First author DOI 10.1016/j.gene.2011.09.029↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xuejiao Wu · 2 shared papers, 2020–2025 · strength 0.45
  2. Zilin Yang · 2 shared papers, 2020–2025 · strength 0.45
  3. Weiyan Yao · 2 shared papers, 2020–2025 · strength 0.45
  4. Jiewei Lin · 2 shared papers, 2022–2025 · strength 0.31
  5. Yizhi Cao · 2 shared papers, 2022–2025 · strength 0.31
  6. Kai Qin · 2 shared papers, 2022–2025 · strength 0.31
  7. Jin Ma · 2 shared papers, 2018–2019 · strength 0.26
  8. Yuanchi Weng · 2 shared papers, 2018–2019 · strength 0.26
  9. Baiyong Shen · 2 shared papers, 2012–2025 · strength 0.22
  10. Jiayu Lin · 1 shared paper, 2025 · strength 0.18
  11. Shuyu Zhai · 1 shared paper, 2025 · strength 0.18
  12. Yihao Liu · 1 shared paper, 2025 · strength 0.18
  13. Siyi Zou · 1 shared paper, 2025 · strength 0.18
  14. Chenlei Wen · 1 shared paper, 2025 · strength 0.18
  15. Wenxin Qi · 1 shared paper, 2025 · strength 0.18
  16. Pengyi Liu · 1 shared paper, 2025 · strength 0.18
  17. Liu Yang · 1 shared paper, 2025 · strength 0.18
  18. Chenghong Peng · 2 shared papers, 2012–2022 · strength 0.17
  19. Jun Zhang Zhang · 1 shared paper, 2019 · strength 0.14
  20. Zengyu Feng · 1 shared paper, 2022 · strength 0.13
  21. Lijie Han · 1 shared paper, 2022 · strength 0.13
  22. Kexian Li · 1 shared paper, 2022 · strength 0.13
  23. Peng Chen · 1 shared paper, 2022 · strength 0.13
  24. Lingxi Jiang · 1 shared paper, 2022 · strength 0.13
  25. Yongsheng Jiang · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.